Amgen to present new data on Repatha at ESC Congress

Amgen will present 11 abstracts at the European Society of Cardiology (ESC) Congress in Rome, including new data on Repatha (evolocumab), between Aug. 27-30.

Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor used in treating high cholesterol. 
 
"Amgen is committed to further advancing our scientific understanding of Repatha and how it can benefit patients with cardiovascular disease and hypercholesterolemia," Amgen EVP of Research and Development Dr. Sean E. Harper said. "The Repatha clinical development program has clearly demonstrated the medicine's ability to deliver meaningful LDL cholesterol reduction in appropriate patients. The findings presented at ESC 2016, alongside the six new clinical trials that have begun in the last year, will better define the benefit of Repatha for the many patients who continue to struggle with hypercholesterolemia."
 
The abstracts present the data evaluating Repatha for treating high cholesterol and heterozygous familial hypercholesterolemia (HeFH). Amegen will also present a Rapid Fire Abstract on the diagnosis and prevalence of familial hypercholesterolemia (FH). 
 
In addition to the abstracts on Repatha, Amgen will present abstracts on statin therapies, myocardial infarctions, FH and low-density lipoprotein-cholesterol (LDL-C) levels in high-risk patients.